Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
← catalyst calendarNCT06619860 · readout in 218 d
Sponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300estimated
Sites
47
Countries
Canada, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-18 | actual | When the study began enrolling |
| Primary completion | 2027-03-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-22 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetic Peripheral Neuropathic Pain
Interventions
- Drug: VX-993
- Drug: Pregabalin
- Drug: Placebo (matched to pregabalin)
- Drug: Placebo (matched to VX-993)
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in the Weekly Average of Daily Pain Intensity on the Numeric Pain Rating Scale (NPRS) at Week 12
measured From Baseline up to Week 12
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed